GoodRx and Surescripts Launch Partnership to Boost Patient Prescription Price Transparency

Reuters01-13
GoodRx and Surescripts Launch Partnership to Boost Patient Prescription Price Transparency

GoodRx Holdings Inc. has announced an exclusive partnership with Surescripts, the nation’s leading health intelligence network, to advance patient price transparency. As part of this collaboration, Surescripts will integrate GoodRx’s prescription savings into its new product, Script Corner™, which aims to provide patients with upfront clarity on medication pricing and savings options. Script Corner will first be available through select health systems in Illinois and Texas in late January, with plans to expand nationwide throughout 2026. The partnership seeks to help reduce prescription abandonment, improve medication adherence, and enhance the overall medication experience for patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GoodRx Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260113093588) on January 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment